We are live on
!
Find out more
Pacer Advisors Portfolio holdings
AUM
$35.6B
1-Year Est. Return
18.19%
This Fund
S&P 500
This Quarter
Est. Return
+6.36%
1 Year Est. Return
+18.19%
3 Year Est. Return
+46.13%
5 Year Est. Return
+70.99%
10 Year Est. Return
+394.12%
AUM
$5.75B
AUM Growth
+$430M
(+8.1%)
Cap. Flow
-$1.1B
Cap. Flow
% of AUM
-19.08%
Top 10 Holdings %
Top 10 Hldgs %
27.15%
Holding
1,587
New
76
Increased
378
Reduced
937
Closed
183
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Newmont
NEM
|
+$6.27M |
| 2 |
TJX Companies
TJX
|
+$5.89M |
| 3 |
General Mills
GIS
|
+$5.87M |
| 4 |
HP
HPQ
|
+$5.84M |
| 5 |
Ford
F
|
+$5.38M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$16.7M |
| 2 |
Amazon
AMZN
|
+$14.9M |
| 3 |
Iron Mountain
IRM
|
+$14.6M |
| 4 |
Microsoft
MSFT
|
+$12.9M |
| 5 |
GDS Holdings
GDS
|
+$9.75M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Real Estate | 17.47% |
| 2 | Technology | 14.6% |
| 3 | Consumer Discretionary | 9.29% |
| 4 | Healthcare | 7.36% |
| 5 | Communication Services | 6.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1276
Precigen
PGEN
$1.97B
| $60K | ﹤0.01% |
8,708
+5,202
| +148% | +$44K |
|
1277
Arcus Biosciences
RCUS
$3.4B
| $60K | ﹤0.01% |
2,145
+66
| +3% | +$2.3K |
|
1278
Xencor
XNCR
$1.48B
| $60K | ﹤0.01% |
1,390
-292
| -17% | -$13.8K |
|
|
TCRR
1279
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $60K | ﹤0.01% |
2,705
+1,624
| +150% | +$44.3K |
|
|
ATNX
1280
DELISTED
Athenex, Inc. Common Stock
ATNX
| $60K | ﹤0.01% |
702
+489
| +230% | +$93.7K |
|
1281
Alector
ALEC
$169M
| $59K | ﹤0.01% |
2,918
-1,636
| -36% | -$29.3K |
|
1282
Celldex Therapeutics
CLDX
$2.79B
| $58K | ﹤0.01% |
2,828
-828
| -23% | -$19K |
|
1283
Scholar Rock
SRRK
$5.92B
| $58K | ﹤0.01% |
1,138
+662
| +139% | +$36.6K |
|
1284
Black Diamond Therapeutics
BDTX
$101M
| $57K | ﹤0.01% |
2,369
+1,276
| +117% | +$34.4K |
|
1285
Travere Therapeutics
TVTX
$5.2B
| $57K | ﹤0.01% |
2,293
+744
| +48% | +$20.6K |
|
|
HEP
1286
DELISTED
Holly Energy Partners, L.P.
HEP
| $57K | ﹤0.01% |
2,984
+291
| +11% | +$4.8K |
|
|
ADVM
1287
DELISTED
Adverum Biotechnologies
ADVM
| $56K | ﹤0.01% |
570
+35
| +7% | +$4.2K |
|
|
EPZM
1288
DELISTED
Epizyme, Inc
EPZM
| $56K | ﹤0.01% |
6,390
+882
| +16% | +$9.13K |
|
|
YMAB
1289
DELISTED
Y-mAbs Therapeutics
YMAB
| $55K | ﹤0.01% |
1,812
+1,048
| +137% | +$43K |
|
1290
Ocugen
OCGN
$420M
| $53K | ﹤0.01% |
+7,800
| New | +$51.9K |
|
1291
Teladoc Health
TDOC
$1.69B
| $52K | ﹤0.01% |
285
-1,254
| -81% | -$291K |
|
1292
CEL-SCI Corp
CVM
$21M
| $51K | ﹤0.01% |
113
+28
| +33% | +$15.3K |
|
1293
Viking Therapeutics
VKTX
$3.93B
| $51K | ﹤0.01% |
8,140
-232
| -3% | -$1.63K |
|
1294
Rigel Pharmaceuticals
RIGL
$712M
| $50K | ﹤0.01% |
1,464
+199
| +16% | +$7.88K |
|
|
TBIO
1295
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $50K | ﹤0.01% |
3,006
-634
| -17% | -$14.4K |
|
1296
Curis
CRIS
$9.41M
| $49K | ﹤0.01% |
+11
| New | +$46K |
|
1297
Keros Therapeutics
KROS
$199M
| $49K | ﹤0.01% |
790
+358
| +83% | +$22.7K |
|
1298
Nurix Therapeutics
NRIX
$2.51B
| $49K | ﹤0.01% |
1,581
+1,042
| +193% | +$39.4K |
|
1299
Prelude Therapeutics
PRLD
$370M
| $49K | ﹤0.01% |
+1,126
| New | +$74.7K |
|
|
CPRX
1300
DELISTED
Catalyst Pharmaceutical
CPRX
| $47K | ﹤0.01% |
10,206
+1,598
| +19% | +$6.35K |
|
Similar funds
SAM
Pacer Advisors's Q1 2021 Portfolio in Review
As of Q1 2021, Pacer Advisors held 1,587 positions worth $5.75B, up 8.1% from $5.32B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Pacer Advisors withdrew a net $1.1B in Q1 2021, closing 183 positions and reducing 937 holdings. Its most notable exit was Rithm Capital, an estimated $4.39M position sold in full.
By sector, the portfolio is most concentrated in Real Estate at 17% of assets, down from 18% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Pacer Advisors opened a new position in Aerojet Rocketdyne Holdings worth $3.39M.
- Pacer Advisors's largest Q1 2021 buy was Aerojet Rocketdyne Holdings: 72,150 shares worth $3.39M.
- Pacer Advisors added most to Newmont in Q1 2021, an estimated $6.27M increase.
- Pacer Advisors's biggest Q1 2021 reduction was Apple, cutting an estimated $16.7M.
- Pacer Advisors fully exited Rithm Capital in Q1 2021, selling an estimated $4.39M.
- Pacer Advisors's ten largest holdings make up 27% of its $5.75B portfolio in Q1 2021.
- Pacer Advisors opened 76 new positions and closed 183 in Q1 2021.
- Pacer Advisors's portfolio value rose 8.1% quarter-over-quarter to $5.75B.
Based on Pacer Advisors's 13F filing for Q1 2021, filed 5 Apr 2021.